Roche's Hivid
Executive Summary
NDA filing completed Oct. 31. Hoffmann-La Roche began a rolling NDA for Hivid (ddC or zalcitabine) during the summer. The company is seeking two indications: treatment of HIV-infected individuals who have failed AZT therapy or developed an intolerance; and a first-line indication for the use of HIVID and AZT in combination. There are currently 8,000 people receiving ddC in ongoing clinical trials and in an expanded access program, begun in June 1990. . . .